Health
Low concentration atropine and myopia: a narrative review of the evidence for United Kingdom based practitioners
Huang J, Wen D, Wang Q, McAlinden C, Flitcroft I, Chen H, et al. Efficacy Comparison of 16 Interventions for Myopia Control in Children: A Network Meta-analysis. Ophthalmology 2016;123:697–708.
Siatkowski RM, Cotter S, Miller JM, Scher CA, Crockett RS, Novack GD, et al. Safety and efficacy of 2% pirenzepine ophthalmic gel in children with myopia: a 1-year, multicenter, double-masked, placebo-controlled parallel study. Arch Ophthalmol. 2004;122:1667–74.
Fricke T, Hurairah H, Huang Y, Ho SM. Pharmacological interventions in myopia management. Community Eye Health. 2019;32:21–2.
Mezer E, Zloto O, Farzavandi SK, Gomez-de-Liano RM, Sprunger DT, Wygnanski-Jaffe T. Current trends to decrease myopia progression survey: an IPOSC global study. J Am Assoc Pediatr Ophthalmol Strabismus JAAPOS. 2018;22:e73.
McBrien NA, Moghaddam HO, Reeder AP. Atropine reduces myopia and eye enlargement via a nonaccommodative mechanism. Invest Ophthalmol Vis Sci. 1993;34:205–15.
Upadhyay A, Beuerman RW. Biological Mechanisms of Atropine Control of Myopia. Eye Contact Lens. 2020;46:129–35.
Phillips JR, Khalaj M, McBrien NA. Induced myopia associated with increased scleral creep in chick and tree shrew eyes. Invest Ophthalmol Vis Sci. 2000;41:2028–34.
Metlapally R, Wildsoet CF. Scleral Mechanisms Underlying Ocular Growth and Myopia. Prog Mol Biol Transl Sci. 2015;134:241–8.
Curtin BJ, Iwamoto T, Renaldo DP. Normal and staphylomatous sclera of high myopia. An electron microscopic study. Arch Ophthalmol Chic Ill 1960. 1979;97:912–5.
Avetisov ES, Savitskaya NF, Vinetskaya MI, Iomdina EN. A study of biochemical and biomechanical qualities of normal and myopic eye sclera in humans of different age groups. Metab Pediatr Syst Ophthalmol. 1983;7:183–8.
Barathi VA, Weon SR, Beuerman RW. Expression of muscarinic receptors in human and mouse sclera and their role in the regulation of scleral fibroblasts proliferation. Mol Vis. 2009;15:1277–93.
Lind GJ, Chew SJ, Marzani D, Wallman J. Muscarinic acetylcholine receptor antagonists inhibit chick scleral chondrocytes. Invest Ophthalmol Vis Sci. 1998;39:2217–31.
Carr BJ, Mihara K, Ramachandran R, Saifeddine M, Nathanson NM, Stell WK, et al. Myopia-Inhibiting Concentrations of Muscarinic Receptor Antagonists Block Activation of Alpha2A-Adrenoceptors In Vitro. Invest Ophthalmol Vis Sci. 2018;59:2778–91.
Barathi VA, Chaurasia SS, Poidinger M, Koh SK, Tian D, Ho C, et al. Involvement of GABA transporters in atropine-treated myopic retina as revealed by iTRAQ quantitative proteomics. J Proteome Res. 2014;13:4647–58.
Chiang STH, Chen TL, Phillips JR. Effect of Optical Defocus on Choroidal Thickness in Healthy Adults With Presbyopia. Invest Ophthalmol Vis Sci. 2018;59:5188–93.
Marzani D, Wallman J. Growth of the two layers of the chick sclera is modulated reciprocally by visual conditions. Invest Ophthalmol Vis Sci. 1997;38:1726–39.
Aldakhil S The Effect of Optical Defocus on the Choroidal Thickness: A Review. Open Ophthalmol J [Internet]. 2021 Dec 28 [cited 2022 Jul 29];15. Available from: https://openophthalmologyjournal.com/VOLUME/15/PAGE/283/FULLTEXT/
Chiang STH, Phillips JR. Effect of Atropine Eye Drops on Choroidal Thinning Induced by Hyperopic Retinal Defocus. J Ophthalmol. 2018;2018:8528315.
Chiang STH, Turnbull PRK, Phillips JR. Additive effect of atropine eye drops and short-term retinal defocus on choroidal thickness in children with myopia. Sci Rep. 2020;10:18310.
Tan J, Deng ZH, Liu SZ, Wang JT, Huang C. TGF-beta2 in human retinal pigment epithelial cells: expression and secretion regulated by cholinergic signals in vitro. Curr Eye Res. 2010;35:37–44.
Seko Y, Tanaka Y, Tokoro T. Influence of bFGF as a potent growth stimulator and TGF-beta as a growth regulator on scleral chondrocytes and scleral fibroblasts in vitro. Ophthalmic Res. 1995;27:144–52.
Yam JC, Jiang Y, Lee J, Li S, Zhang Y, Sun W, et al. The Association of Choroidal Thickening by Atropine With Treatment Effects for Myopia: Two-Year Clinical Trial of the Low-concentration Atropine for Myopia Progression (LAMP) Study. Am J Ophthalmol. 2021;237:130–8.
Tian J, Wei S, Li S, An W, Bai W, Liang X, et al. The effect of atropine 0.01% eyedrops on relative peripheral refraction in myopic children. Eye Lond Engl. 2023;37:356–61.
Donders FC. On the anomalies of accommodation and refraction of the eye. New Sydenham Soc. 1864;34:443–5.
GALVIS V, TELLO A, PARRA MM, MERAYO-LLOVES J, LARREA J, JULIAN RODRIGUEZ C, et al. Topical Atropine in the Control of Myopia. Med Hypothesis Discov Innov Ophthalmol. 2016;5:78–88.
Pollock WBI. The Reduction of Myopia in Children of School Age *Presented to the Association of School Medical Officers of Scotland on 18th March, 1915. Glas Med J. 1916;86:214–9.
Gostin S. Prophylatic management of progressive myopia. South Med J. 1962;55:916–20.
Bedrossian RH. The effect of atropine on myopia. Ophthalmology 1979;86:713–9.
Kennedy RH. Progression of myopia. Trans Am Ophthalmol Soc. 1995;93:755–800.
Kelly TS, Chatfield C, Tustin G. Clinical assessment of the arrest of myopia. Br J Ophthalmol. 1975;59:529–38.
Gruber E. The treatment of myopia with atropine: A clinical study. Excerpta Med Int Congr Ser. 1979;1:1212–6.
Brodstein RS, Brodstein DE, Olson RJ, Hunt SC, Williams RR. The Treatment of Myopia with Atropine and Bifocals: A Long-term Prospective Study. Ophthalmology 1984;91:1373–8.
Gimbel HV. The control of myopia with atropine. Can J Ophthalmol J Can Ophtalmol. 1973;8:527–32.
Yen MY, Liu JH, Kao SC, Shiao CH. Comparison of the effect of atropine and cyclopentolate on myopia. Ann Ophthalmol. 1989;21:180–2.
Shih YF, Chen CH, Chou AC, Ho TC, Lin LL, Hung PT. Effects of different concentrations of atropine on controlling myopia in myopic children. J Ocul Pharm Ther. 1999;15:85–90.
Yam JC, Li FF, Zhang X, Tang SM, Yip BHK, Kam KW, et al. Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 2 Report. Ophthalmology 2020;127:910–9.
Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, Wong E, et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. Ophthalmology 2019;126:113–24.
Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, et al. Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2). Ophthalmology 2012;119:347–54.
Chia A, Lu QS, Tan D. Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2. Ophthalmology 2016;123:391–9.
Chua WH, Balakrishnan V, Chan YH, Tong L, Ling Y, Quah BL, et al. Atropine for the treatment of childhood myopia. Ophthalmology 2006;113:2285–91.
Tong L, Huang XL, Koh ALT, Zhang XE, Tan DTH, Chua WH. Atropine for the Treatment of Childhood Myopia: Effect on Myopia Progression after Cessation of Atropine. Ophthalmology 2009;116:572–9.
Bullimore MA, Berntsen DA. Low-Dose Atropine for Myopia Control: Considering All the Data. JAMA Ophthalmol. 2018;136:303.
Yam JC, Zhang XJ, Zhang Y, Wang YM, Tang SM, Li FF, et al. Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout: Phase 3 Report. Ophthalmology 2022;129:308–21.
Bullimore MA, Brennan NA. Efficacy in Myopia Control: The Low-Concentration Atropine for Myopia Progression (LAMP) Study. Ophthalmology 2023;130:771–2.
Loh KL, Lu QS, Tan D, Chia A. Risk Factors for Progressive Myopia in the Atropine Therapy for Myopia Study. Am J Ophthalmol. 2015;159:945–9.
Li FF, Zhang Y, Zhang X, Kei Yip BH, Tang SM, Kam KW, et al. Age effect on treatment responses to 0.05%, 0.025%, and 0.01% atropine: Low-concentration Atropine for Myopia Progression (LAMP) Study. Ophthalmology 2021;07:07.
Hu Y, Ding X, Guo X, Chen Y, Zhang J, He M. Association of Age at Myopia Onset With Risk of High Myopia in Adulthood in a 12-Year Follow-up of a Chinese Cohort. JAMA Ophthalmol. 2020;138:1129–34.
Cooper J, Eisenberg N, Schulman E, Wang FM. Maximum atropine dose without clinical signs or symptoms. Optom Vis Sci Publ Am Acad Optom. 2013;90:1467–72.
Lee CY, Sun CC, Lin YF, Lin KK. Effects of topical atropine on intraocular pressure and myopia progression: a prospective comparative study. BMC Ophthalmol. 2016;16:114.
Chia A, Li W, Tan D, Luu CD. Full-field electroretinogram findings in children in the atropine treatment for myopia (ATOM2) study. Doc Ophthalmol Adv Ophthalmol. 2013;126:177–86.
Luu CD, Lau AMI, Koh AHC, Tan D. Multifocal electroretinogram in children on atropine treatment for myopia. Br J Ophthalmol. 2005;89:151–3.
Saxena R, Dhiman R, Gupta V, Kumar P, Matalia J, Roy L, et al. Atropine for treatment of childhood myopia in India (I-ATOM): multicentric randomized trial. Ophthalmology 2021;02:02.
Hieda O, Hiraoka T, Fujikado T, Ishiko S, Hasebe S, Torii H, et al. Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study. Jpn J Ophthalmol. 2021;14:14.
Fu A, Stapleton F, Wei L, Wang W, Zhao B, Watt K, et al. Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression. Br J Ophthalmol. 2020;104:1535–41.
Cui C, Li X, Lyu Y, Wei L, Zhao B, Yu S, et al. Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial. Sci Rep. 2021;11:22267.
Lee SSY, Lingham G, Blaszkowska M, Sanfilippo PG, Koay A, Franchina M, et al. Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: A randomised clinical trial. Clin Exp Ophthalmol. 2022;50:1001–12.
Zadnik K, Schulman E, Flitcroft I, Fogt JS, Blumenfeld LC, Fong TM, et al. Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial. JAMA Ophthalmol. 2023;e232097. https://doi.org/10.1001/jamaophthalmol.2023.2097. Epub ahead of print.
R Handbook: What are Least Square Means? [Internet]. [cited 2023 Jun 17]. Available from: https://rcompanion.org/handbook/G_05.html
Bausch & Lomb Incorporated. A Multicenter, Double-Masked, Randomized, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of Atropine 0.1% and 0.01% Ophthalmic Solutions Administered With a Microdose Dispenser for the Reduction of Pediatric Myopia Progression (The CHAPERONE Study) [Internet]. clinicaltrials.gov; 2021 Dec [cited 2022 Apr 24]. Report No.: NCT03942419. Available from: https://clinicaltrials.gov/ct2/show/NCT03942419
Vyluma, Inc. A 3-Arm Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study of NVK-002 in Children With Myopia [Internet]. clinicaltrials.gov; 2022 Feb [cited 2022 Apr 24]. Report No.: NCT03350620. Available from: https://clinicaltrials.gov/ct2/show/NCT03350620
Sydnexis, Inc. A Multicenter, Randomized, Double-masked, Vehicle-controlled Study to Assess the Safety and Efficacy of SYD-101 Ophthalmic Solution for the Treatment of Myopia in Children [Internet]. clinicaltrials.gov; 2022 Jan [cited 2022 Apr 24]. Report No.: NCT03918915. Available from: https://clinicaltrials.gov/ct2/show/NCT03918915
Clinical Trials register – Search for Atropine [Internet]. [cited 2022 Feb 15]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/search?query=Atropine
Gan J, Li SM, Wu S, Cao K, Ma D, He X, et al. Varying Dose of Atropine in Slowing Myopia Progression in Children Over Different Follow-Up Periods by Meta-Analysis. Front Med. 2022;8:756398.
Zhao C, Cai C, Ding Q, Dai H. Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis. BMC Ophthalmol. 2020;20:478.
Bullimore MA, Logan NS. Optical Interventions for Myopia Control. Eye Lond Engl. 2023; https://doi.org.uk/10.1038/s41433-023-02723-5
Kinoshita N, Konno Y, Hamada N, Kanda Y, Shimmura-Tomita M, Kakehashi A. Additive effects of orthokeratology and atropine 0.01% ophthalmic solution in slowing axial elongation in children with myopia: first year results. Jpn J Ophthalmol. 2018;62:544–53.
Kinoshita N, Konno Y, Hamada N, Kanda Y, Shimmura-Tomita M, Kaburaki T, et al. Efficacy of combined orthokeratology and 0.01% atropine solution for slowing axial elongation in children with myopia: a 2-year randomised trial. Sci Rep. 2020;10:11.
Gao C, Wan S, Zhang Y, Han J. The Efficacy of Atropine Combined With Orthokeratology in Slowing Axial Elongation of Myopia Children: A Meta-Analysis. Eye Contact Lens. 2021;47:98–103.
Yang N, Bai J, Liu L. Low concentration atropine combined with orthokeratology in the treatment of axial elongation in children with myopia: A meta-analysis. Eur J Ophthalmol. 2022;32:221–8.
Zhou H, Zhao G, Li Y. Adjunctive effects of orthokeratology and atropine 0.01% eye drops on slowing the progression of myopia. Clin Exp Optom. 2022;105:520–6.
Tan Q, Ng ALK, Choy BNK, Cheng GPM, Woo VCP, Cho P. One-year results of 0.01% atropine with orthokeratology (AOK) study: a randomised clinical trial. Ophthalmic Physiol Opt. 2020;40:557–66.
Bullimore MA, Brennan NA. Efficacy in Myopia Control: Does Race Matter? Optom Vis Sci Publ Am Acad Optom. 2023;100:5–8.
Sacchi M, Serafino M, Villani E, Tagliabue E, Luccarelli S, Bonsignore F, et al. Efficacy of atropine 0.01% for the treatment of childhood myopia in European patients. Acta Ophthalmol (Copenh). 2019;97:e1136–40.
Pérez-Flores I, Macías-Murelaga B, Barrio-Barrio J. A multicenter Spanish study of atropine 0.01% in childhood myopia progression. Sci Rep. 2021;11:21748.
Joachimsen L, Böhringer D, Gross NJ, Reich M, Stifter J, Reinhard T, et al. A Pilot Study on the Efficacy and Safety of 0.01% Atropine in German Schoolchildren with Progressive Myopia. Ophthalmol Ther. 2019;8:427–33.
Azuara-Blanco A, Logan N, Strang N, Saunders K, Allen PM, Weir R, et al. Low-dose (0.01%) atropine eye-drops to reduce progression of myopia in children: a multicentre placebo-controlled randomised trial in the UK (CHAMP-UK)—study protocol. Br J Ophthalmol. 2020;104:950–5.
McCrann S, Flitcroft I, Strang NC, Saunders KJ, Logan NS, Lee SS, et al. Myopia Outcome Study of Atropine in Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol. HRB Open Res. 2019;2:15.
Bullimore MA, Brennan NA. Myopia Control: Why Each Diopter Matters. Optom Vis Sci Publ Am Acad Optom. 2019;96:463–5.
COMET Group. Myopia Stabilization and Associated Factors Among Participants in the Correction of Myopia Evaluation Trial (COMET). Invest Ophthalmol Vis Sci. 2013;54:7871–84.
Brennan NA, Toubouti YM, Cheng X, Bullimore MA. Efficacy in myopia control. Prog Retin Eye Res. 2021;83:100923.
Klaver C CW, Polling JR, Group EMR. Myopia management in the Netherlands. Ophthalmic Physiol Opt. 2020;40:230–40.
Parssinen O, Kauppinen M, Viljanen A. The progression of myopia from its onset at age 8-12 to adulthood and the influence of heredity and external factors on myopic progression. A 23-year follow-up study. Acta Ophthalmol (Copenh). 2014;92:730–9.
Tsai HR, Chen TL, Wang JH, Huang HK, Chiu CJ. Is 0.01% Atropine an Effective and Safe Treatment for Myopic Children? A Systemic Review and Meta-Analysis. J Clin Med. 2021;10:3766.
Wei-Lin AC. The Use of Atropine 0.01% in the Prevention and Control of Myopia (ATOM3) [Internet]. clinicaltrials.gov; 2017 Oct [cited 2022 Feb 16]. Report No.: NCT03140358. Available from: https://clinicaltrials.gov/ct2/show/NCT03140358
Jethani J. Efficacy of low-concentration atropine (0.01%) eye drops for prevention of axial myopic progression in premyopes. Indian J Ophthalmol. 2022;70:238–40.
Fang PC, Chung MY, Yu HJ, Wu PC. Prevention of myopia onset with 0.025% atropine in premyopic children. J Ocul Pharm Ther J Assoc Ocul Pharm Ther. 2010;26:341–5.
Yam JC, Zhang XJ, Zhang Y, Yip BHK, Tang F, Wong ES, et al. Effect of Low-Concentration Atropine Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial. JAMA 2023;329:472–81.
Richdale K, Tomiyama ES, Novack GD, Bullimore MA. Compounding of Low-Concentration Atropine for Myopia Control. Eye Contact Lens. 2022;48:489–92.
Berton B, Chennell P, Yessaad M, Bouattour Y, Jouannet M, Wasiak M. et al. Stability of Ophthalmic Atropine Solutions for Child Myopia Control. Pharmaceutics. 2020;12:781
|
Sources 2/ https://www.nature.com/articles/s41433-023-02718-2 The mention sources can contact us to remove/changing this article |
What Are The Main Benefits Of Comparing Car Insurance Quotes Online
LOS ANGELES, CA / ACCESSWIRE / June 24, 2020, / Compare-autoinsurance.Org has launched a new blog post that presents the main benefits of comparing multiple car insurance quotes. For more info and free online quotes, please visit https://compare-autoinsurance.Org/the-advantages-of-comparing-prices-with-car-insurance-quotes-online/ The modern society has numerous technological advantages. One important advantage is the speed at which information is sent and received. With the help of the internet, the shopping habits of many persons have drastically changed. The car insurance industry hasn't remained untouched by these changes. On the internet, drivers can compare insurance prices and find out which sellers have the best offers. View photos The advantages of comparing online car insurance quotes are the following: Online quotes can be obtained from anywhere and at any time. Unlike physical insurance agencies, websites don't have a specific schedule and they are available at any time. Drivers that have busy working schedules, can compare quotes from anywhere and at any time, even at midnight. Multiple choices. Almost all insurance providers, no matter if they are well-known brands or just local insurers, have an online presence. Online quotes will allow policyholders the chance to discover multiple insurance companies and check their prices. Drivers are no longer required to get quotes from just a few known insurance companies. Also, local and regional insurers can provide lower insurance rates for the same services. Accurate insurance estimates. Online quotes can only be accurate if the customers provide accurate and real info about their car models and driving history. Lying about past driving incidents can make the price estimates to be lower, but when dealing with an insurance company lying to them is useless. Usually, insurance companies will do research about a potential customer before granting him coverage. Online quotes can be sorted easily. Although drivers are recommended to not choose a policy just based on its price, drivers can easily sort quotes by insurance price. Using brokerage websites will allow drivers to get quotes from multiple insurers, thus making the comparison faster and easier. For additional info, money-saving tips, and free car insurance quotes, visit https://compare-autoinsurance.Org/ Compare-autoinsurance.Org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc. "Online quotes can easily help drivers obtain better car insurance deals. All they have to do is to complete an online form with accurate and real info, then compare prices", said Russell Rabichev, Marketing Director of Internet Marketing Company. CONTACT: Company Name: Internet Marketing CompanyPerson for contact Name: Gurgu CPhone Number: (818) 359-3898Email: [email protected]: https://compare-autoinsurance.Org/ SOURCE: Compare-autoinsurance.Org View source version on accesswire.Com:https://www.Accesswire.Com/595055/What-Are-The-Main-Benefits-Of-Comparing-Car-Insurance-Quotes-Online View photos
to request, modification Contact us at Here or [email protected]
 |
 |
 |
